Delivery Order SPE2DB20D9127-SPE2DB22FD3WC

Award Date 5/4/22
Potential Completion Date 5/25/22
Potential Value $30K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of NEXPLANON 68 MG IMPLANTS. The contract, valued at $8,576.28, has an ultimate completion date of July 12, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued at up to $499,999,999, that allows the DLA to issue firm fixed-price delivery orders for a...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a for-profit woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The contract, with a potential value of $10,720.35, has a completion date of February 28, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that offers a comprehensive range of brand and generic pharmaceutical products to U.S. government agencies,...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The contract has a potential value of $3,573.45 and a completion date of January 29, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that holds multiple federal contracts and indefinite delivery vehicles (IDVs) with DLA to supply a variety of pharmaceuticals and medical products to military...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,728.84 firm fixed-price contract is for the delivery of NEXPLANON 68 MG IMPLANTS to support the medical supply needs of military health facilities. This award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which enables...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of NEXPLANON 68 MG IMPLANTS. The contract, valued at $33,326.88, has an ultimate completion date of February 12, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and...
The U.S. Defense Logistics Agency awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The contract has a potential value of $12,864.42 and a completion date of March 20, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that has received numerous prime and subcontracts from the Department of Veterans Affairs and Department of Defense to deliver a wide range of pharmaceutical...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Nexplanon 68 mg implants. The contract, valued at $7,146.90, is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to $499,999,999, that covers a wide range of pharmaceutical products to support the medical supply needs of Department of Defense (DoD) healthcare...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, with a ceiling value of $6,837.40 and a period of performance through May 8, 2023. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and DLA, valued at up to $499,999,999, which allows the DLA to...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Nexplanon 68 mg implants to the Defense Logistics Agency (DLA) Medical Supply Chain. The firm fixed-price delivery order, valued at $2,858.76, has a period of performance through July 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award vehicle, under...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed-price delivery order worth $3,573.45 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NEXPLANON 68 MG IMPLANTS. This order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with the DLA, valued up to $4,999,999 through 2025, which enables the agency to order a broad range of pharmaceutical products to support military health...
  • SPE2DB20D9127
    Indefinite Delivery Contract
  • SPE2DB20D9127-SPE2DB22FD3WC
    Delivery Order

This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The $30,200.64 firm fixed-price delivery order was awarded on May 4, 2022, with a completion date of May 25, 2022. DMS Pharmaceutical Group is a key supplier of pharmaceutical products and medical supplies to the Department of Defense (DoD) healthcare system under a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA. This IDC, valid through November 2026, enables the DLA to issue delivery orders for a comprehensive range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military health facilities nationwide. The contract award is not associated with any set-aside designation.

Generated 2/27/25, 12:11 PM